The course of posttransplant hepatitis c infection: Comparative impact of donor and recipient source of the favorable IL28B genotype and other variables

Transplantation

Volumn 94, Issue 2, 2012, Pages 197-203

  Duarte Rojo, Andres ^a   Veldt, Bart J ^b   Goldstein, David D ^c   Tillman, Hans L ^c   Watt, Kymberly D ^a   Heimbach, Julie K ^a   McHutchison, John G ^c   Poterucha, John J ^a   Vargas Vorackova, Florencia ^d   Charlton, Michael R ^a  

^a MAYO CLINIC   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Acute cellular rejection; Fibrosis; Histologic grade; Interferon L; Survival; Sustained virological response

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IL28B GENE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN DONOR; OUTCOME ASSESSMENT; POSTTRANSPLANT HEPATITIS C; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETRANSPLANTATION; SURVIVAL; VIRUS GENE; VIRUS LOAD;

AGED; ALANINE TRANSAMINASE; FEMALE; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; REOPERATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 84864280702     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182547551     Document Type: Article

References (30)

1. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51: 31.
2. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504.
3. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833.
4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399.
5. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798.
6. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100.
8. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138: 1338.
9. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
10. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120.
11. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virusYrelated graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852.
12. Prieto M, Berenguer M, Rimola A, et al. Liver transplantation in hepatitis C. A Spanish multi-centre experience. Eur J Gastroenterol Hepatol 1998; 10: 771.
13. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
14. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577.
15. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317.
16. Eurich D, Boas-Knoop S, Ruehl M, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virusYinduced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289.
17. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322.
18. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al
19. Megjugorac NJ, Gallagher GE, Gallagher G. Modulation of human plasmacytoid DCfunction by IFN-lambda1 (IL-29). J Leukoc Biol 2009; 86: 1359.
20. Gallagher G, Megjugorac NJ, Yu RY, et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 2010; 30: 603.
21. Jordan WJ, Eskdale J, Srinivas S, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the TH1/TH2 response. Genes Immun 2007; 8: 254.
22. Morrow MP, Pankhong P, Laddy DJ, et al. Comparative ability of IL- 12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113: 5868.
23. Barth H, Rybczynska J, Patient R, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011; 54: 1135.
24. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499.
25. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021.
26. Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980.
27. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127.
28. Barreiro P, Pineda JA, Rallon N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virusYhepatitis C virusYcoinfected patients receiving antiretroviral therapy. J Infect Dis 2011; 203: 1629.
29. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792.
30. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Surg Pathol 1995; 19: 1409.